PL1900362T3 - Pochodne alfa-aminoamidu użyteczne w leczeniu zaburzeń uzależnieniowych - Google Patents

Pochodne alfa-aminoamidu użyteczne w leczeniu zaburzeń uzależnieniowych

Info

Publication number
PL1900362T3
PL1900362T3 PL07022078T PL07022078T PL1900362T3 PL 1900362 T3 PL1900362 T3 PL 1900362T3 PL 07022078 T PL07022078 T PL 07022078T PL 07022078 T PL07022078 T PL 07022078T PL 1900362 T3 PL1900362 T3 PL 1900362T3
Authority
PL
Poland
Prior art keywords
treatment
alfa
addictive disorders
derivatives useful
aminoamide derivatives
Prior art date
Application number
PL07022078T
Other languages
English (en)
Inventor
Claudia Besana
Elena Barbanti
Emanuela Izzo
Florian Thaler
Ruggero Fariello
Patricia Salvati
Luca Benatti
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Publication of PL1900362T3 publication Critical patent/PL1900362T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
PL07022078T 2004-04-22 2005-04-19 Pochodne alfa-aminoamidu użyteczne w leczeniu zaburzeń uzależnieniowych PL1900362T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04009532A EP1588704A1 (en) 2004-04-22 2004-04-22 Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
EP05736365A EP1737438B1 (en) 2004-04-22 2005-04-19 Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome
EP07022078A EP1900362B1 (en) 2004-04-22 2005-04-19 Alfa-aminoamide derivatives useful in the treatment of addictive disorders

Publications (1)

Publication Number Publication Date
PL1900362T3 true PL1900362T3 (pl) 2011-06-30

Family

ID=34924693

Family Applications (2)

Application Number Title Priority Date Filing Date
PL07022078T PL1900362T3 (pl) 2004-04-22 2005-04-19 Pochodne alfa-aminoamidu użyteczne w leczeniu zaburzeń uzależnieniowych
PL05736365T PL1737438T3 (pl) 2004-04-22 2005-04-19 Pochodne Alfa-aminoamidu użyteczne do leczenia zespołu niespokojnych nóg

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL05736365T PL1737438T3 (pl) 2004-04-22 2005-04-19 Pochodne Alfa-aminoamidu użyteczne do leczenia zespołu niespokojnych nóg

Country Status (25)

Country Link
US (2) US8445513B2 (pl)
EP (3) EP1588704A1 (pl)
JP (1) JP5020069B2 (pl)
KR (2) KR101238377B1 (pl)
CN (1) CN1942179B (pl)
AT (2) ATE494890T1 (pl)
AU (1) AU2005235428B2 (pl)
BR (2) BRPI0509976B8 (pl)
CA (1) CA2563674C (pl)
CY (2) CY1108494T1 (pl)
DE (2) DE602005009162D1 (pl)
DK (2) DK1900362T3 (pl)
ES (2) ES2357559T3 (pl)
HR (2) HRP20080593T3 (pl)
IL (1) IL178732A (pl)
ME (2) ME02324B (pl)
MX (1) MXPA06012163A (pl)
NO (2) NO337900B1 (pl)
NZ (1) NZ550664A (pl)
PL (2) PL1900362T3 (pl)
PT (2) PT1900362E (pl)
RS (2) RS50667B (pl)
RU (1) RU2403030C2 (pl)
SI (2) SI1737438T1 (pl)
WO (1) WO2005102300A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
JP4350508B2 (ja) 2001-09-03 2009-10-21 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ガバペンチンまたはその類似体とα−アミノアミドとを含む薬剤組成物およびその鎮痛用途
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
WO2005018627A1 (en) * 2003-08-25 2005-03-03 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
SI1809271T1 (sl) * 2004-09-10 2010-10-29 Newron Pharm Spa Uporaba (R)-(halobenziloksi) benzilamino propanamidov kot selektivnih modulatorjev natrijevih in/ali kalcijevih kanalov
JP2008519811A (ja) * 2004-11-10 2008-06-12 オリオン コーポレーション 下肢静止不能症候群の治療
NZ567540A (en) 2005-12-22 2010-07-30 Newron Pharm Spa 2-Phenylethylamino derivatives as calcium and/or sodium channel modulators
US8946300B2 (en) 2006-04-03 2015-02-03 Teva Pharmaceutical Industries, Ltd. Use of rasagilline for the treatment of restless legs syndrome
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
EA017123B1 (ru) * 2006-06-19 2012-10-30 Ньюрон Фармасьютикалс С.П.А. Способ получения 2-[4-(3- и 2-фторбензилокси)бензиламино]пропанамидов
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
RS56780B1 (sr) 2007-06-15 2018-04-30 Newron Pharm Spa Substituisani derivati 2-[2-(fenil) etilamino]alkanamida i njihova upotreba kao modulatora kanala za natrijum i/ili kalcijum
KR101709498B1 (ko) 2007-12-11 2017-02-23 뉴론 파마슈티칼즈 에스. 피. 에이. 고순도의 2­[4­(3­ 또는 2­플루오로벤질옥시)벤질아미노]프로판아미드의 제조방법
BRPI0821026A2 (pt) * 2007-12-19 2015-06-16 Newron Pharmaceutical S P A Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
CA2794389C (en) 2010-04-27 2016-08-23 Newron Pharmaceuticals S.P.A. Process for the production of ralfinamide methanesulfonate salts or their r-enantiomers
US11278651B2 (en) 2018-10-17 2022-03-22 Gambro Lundia Ab Membrane and device for treating restless leg syndrome
CN114667963B (zh) * 2020-12-24 2024-04-26 中国科学院脑科学与智能技术卓越创新中心 一种非人灵长类动物药物成瘾性评估的装置

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US4049663A (en) * 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4935429A (en) * 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
EP0331620B1 (de) * 1988-03-01 1993-08-11 Birkmayer, Walther, Prof. Dr. Mittel zur Behandlung des Parkinson-Syndroms
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
EP0520325A1 (de) * 1991-06-28 1992-12-30 F.Hoffmann-La Roche & Co. Aktiengesellschaft Verwendung von Monoaminoxidase-B-Hemmern zur Verhütung und Behandlung von Entzugserscheinungen nach Alkohol- und Drogenmissbrauch
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
WO1996037226A2 (en) * 1995-05-26 1996-11-28 Pfizer Inc. Combinations for the treatment of parkinsonism containing selective nmda antagonists
WO1997000511A1 (de) 1995-06-17 1997-01-03 Baumann Guenter Scheibenkörper
GB9515412D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9515411D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa N-(4-substituted-benzyl)-2-aminolactam derivatives
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
GB9727521D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Substituted 2-benzylamino-2-phenyl-acetamide compounds
NZ506262A (en) 1998-01-12 2003-10-31 Deborah Wenzel Composition as an additive to create clear stable solutions and microemulsions with a combustible liquid fuel to improve combustion
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
AU1359801A (en) * 1999-11-05 2001-06-06 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
AU2080201A (en) 1999-12-10 2001-06-18 University Of Cincinnati, The Treatment of addiction disorders
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
EP1406631A4 (en) * 2001-06-13 2005-03-23 Univ Michigan DOPAMIN RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREFOR
PT1511718E (pt) * 2002-05-29 2009-06-12 Hoffmann La Roche Derivados de n-acilaminobenzeno como inibidores selectivos de monoamina-oxidase b
PL203763B1 (pl) 2002-06-24 2009-11-30 Rockwool Int Sposób i urządzenie do wytwarzania wełny mineralnej
US6900354B2 (en) * 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
JP2005060370A (ja) * 2003-07-25 2005-03-10 Kyowa Hakko Kogyo Co Ltd 医薬組成物
EP1524267A1 (en) 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Substituted benzylaminoalkylene heterocycles
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders

Also Published As

Publication number Publication date
ES2357559T3 (es) 2011-04-27
KR101238377B1 (ko) 2013-03-04
HK1099216A1 (en) 2007-08-10
DK1900362T3 (da) 2011-05-09
CA2563674A1 (en) 2005-11-03
NO20064732L (no) 2006-11-22
PL1737438T3 (pl) 2009-01-30
CA2563674C (en) 2012-12-18
BRPI0509976B8 (pt) 2021-05-25
NO337900B1 (no) 2016-07-04
RU2403030C2 (ru) 2010-11-10
WO2005102300A1 (en) 2005-11-03
EP1900362B1 (en) 2011-01-12
ATE494890T1 (de) 2011-01-15
IL178732A (en) 2013-01-31
CY1111656T1 (el) 2015-10-07
BRPI0509976A (pt) 2007-10-16
EP1900362A3 (en) 2009-04-01
JP5020069B2 (ja) 2012-09-05
ES2313330T3 (es) 2009-03-01
HRP20110230T1 (hr) 2011-04-30
EP1900362A2 (en) 2008-03-19
DE602005009162D1 (de) 2008-10-02
CY1108494T1 (el) 2014-04-09
US8445513B2 (en) 2013-05-21
CN1942179A (zh) 2007-04-04
ATE405256T1 (de) 2008-09-15
JP2007533691A (ja) 2007-11-22
US20070203182A1 (en) 2007-08-30
ME02324B (me) 2016-06-20
RS50667B (sr) 2010-06-30
RS51791B (sr) 2011-12-31
MXPA06012163A (es) 2007-01-17
AU2005235428B2 (en) 2010-03-18
US20130217747A1 (en) 2013-08-22
SI1737438T1 (sl) 2008-12-31
NZ550664A (en) 2010-08-27
IL178732A0 (en) 2007-05-15
EP1588704A1 (en) 2005-10-26
PT1737438E (pt) 2008-12-22
BR122020004541B1 (pt) 2021-11-09
NO20150971L (no) 2006-11-22
KR101195819B1 (ko) 2012-11-05
EP1737438A1 (en) 2007-01-03
RU2006137079A (ru) 2008-04-27
EP1737438B1 (en) 2008-08-20
NO338870B1 (no) 2016-10-31
ME01219B (me) 2013-06-20
DK1737438T3 (da) 2008-12-08
KR20070042914A (ko) 2007-04-24
US8697738B2 (en) 2014-04-15
KR20120028399A (ko) 2012-03-22
PT1900362E (pt) 2011-03-09
AU2005235428A1 (en) 2005-11-03
CN1942179B (zh) 2010-08-11
SI1900362T1 (sl) 2011-03-31
BRPI0509976B1 (pt) 2020-10-06
DE602005025941D1 (de) 2011-02-24
HRP20080593T3 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
PL1900362T3 (pl) Pochodne alfa-aminoamidu użyteczne w leczeniu zaburzeń uzależnieniowych
LTC1971601I2 (pl)
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
IL179508A0 (en) 2-substituted-4- heteroaryl-pyrimidines useful for the treatment of proliferative disorders
IL191283A (en) Compositions for treating eye irregularities
ZA200700384B (en) Hydantoin derivatives for the treatment of inflammatory disorders
TW200510301A (en) Novel compounds
TW200510303A (en) Novel compounds
IL188390A0 (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
WO2008011113A3 (en) Thiadiazolidinone derivatives
ZA200805159B (en) Imidazole derivatives for the treatment of gastrointestinal disorders
EP1814535A4 (en) NITROSED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING EYE DISEASES
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
IL189524A0 (en) Imidazole compounds for the treatment of neurological disorders
IL177955A0 (en) Sulfonamide compounds for the treatment of neurodegenerative disorders
PT2366393E (pt) Roflumilaste para o tratamento da hipertensão pulmonar
IL185653A (en) Antibodies that call for the 1-kim salt region
EP1890711A4 (en) COMPOUNDS FOR THE TREATMENT OR PREVENTION OF AMINOXIDASE-RELATED DISEASES OR DISEASES
ZA200800409B (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
EP1937242A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES AND ADDITIVES
WO2006060202A3 (en) Imidazole derivatives for the treatment of psychiatric disorders
WO2006060201A3 (en) Pyrazole derivatives for the treatment of psychiatric disorders
HK1119685A (en) Compounds for the treatment of inflammatory disorders